AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01659307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 1200mg
Description: Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
Study NCT03716141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Platelets Rich Plasma Treatment
Description: For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.
Study NCT03716141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Saline dressing
Description: saline dressing of diabetic wounds will be done
Study NCT03914066 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A group-based treatment of overweight and obesity
Description: The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
Study NCT02567838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Description: Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
Study NCT02567838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Aquagel) was administered rectally prior to probe insertion.
Study NCT04113239 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 16S rRNA gene sequencing
Description: Taking a stool sample for gut microbiome DNA sequencing
Study NCT04113239 — intervention group
Intervention type: GENETIC
Intervention: DNA-microarray genotyping
Description: Taking a saliva sample for genotyping
Study NCT01520857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal Preperitoneal repair of inguinal hernia
Description: Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
Study NCT01520857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transabdominal Preperitoneal repair of inguinal hernia
Description: Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
Study NCT03270293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profhilo
Study NCT01056770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: smallpox vaccine CJ-50300
Description: Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
Study NCT03106610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.
Study NCT03106610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
Study NCT03140007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single operator cholangioscopy
Description: If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
Study NCT03140007 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ERCP guided brushing and biopsy
Description: • If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
Study NCT03119480 — intervention group
Intervention type: DEVICE
Intervention: electronic alerts
Description: electronic alerts for AKI
Study NCT02989688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nepro HP (Abbott Nutrition)
Description: oral nutritional supplement drink with modified carbohydrate composition
Study NCT02989688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortisip compact protein 125 ml + Calogen 20ml (Nutricia)
Description: Fortisip compact protein 125 ml + Calogen 20ml (Nutricia) oral nutritional supplement drink macronutrient matched with standard carbohydrate composition
Study NCT02989688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortisip compact 125 ml (Nutricia)
Description: Fortisip compact 125 ml (Nutricia) oral nutritional supplement drink - standard
Study NCT03657160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vedolizumab Placebo
Description: Vedolizumab placebo-matching IV infusion.
Study NCT03657160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.
Study NCT02572921 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychotherapy
Description: The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:~positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the full life.
Study NCT02572921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
Study NCT00973193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
Study NCT02183571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merck Glucophage® high dose
Description: Part I: Treatment A
Study NCT02183571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS Glucophage® high dose
Description: Part I: Treatment B
Study NCT02183571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merck Glucophage® low dose
Description: Part II: Treatment C
Study NCT02183571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS Glucophage® low dose
Description: Part II: Treatment D
Study NCT01184560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily
Study NCT01184560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sibutramine
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily
Study NCT01184560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily
Study NCT01184560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orlistat
Description: ○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~* Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~* Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily
Study NCT04403880 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: * Optional nasal specimen(s)~* Blood collection
Study NCT03428594 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CKD-11101
Study NCT03428594 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NESP
Study NCT00898079 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies
Study NCT02665143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib and AML induction
Description: The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
Study NCT02485808 — intervention group
Intervention type: OTHER
Intervention: None-observational
Description: For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
Study NCT02485808 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: One time MRI scanning session examining brain structure and function in a resting state and after water consumption.
Study NCT02485808 — intervention group
Intervention type: OTHER
Intervention: Multimodal Automated Sensory Testing System
Description: Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.
Study NCT02485808 — intervention group
Intervention type: OTHER
Intervention: Auditory Sensitivity Test
Description: Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
Study NCT02120443 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ivWatch Model 400
Description: The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
Study NCT00270959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
Study NCT00270959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing is designed to address alcohol and drug use.
Study NCT00270959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-Approved Anti-Anxiety Medications
Description: Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
Study NCT00270959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control
Description: Standard care control includes the usual treatment for injured trauma survivors.
Study NCT03230149 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of the alpha-GAL enzyme activity
Description: Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.
Study NCT01370408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Study NCT01370408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron
Description: Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
Study NCT01370408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Prior to IV chemotherapy - ondansetron 8mg IV \& Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
Study NCT04883801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reviewed clinical records and laboratory results
Description: Retrospectively reviewed clinical records and laboratory results
Study NCT01130688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: Imatinib combined with Zileuton
Study NCT04525248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total colectomy + low resection of rectum
Description: Laparoscopic total colectomy + low resection of rectum
Study NCT04525248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic total colectomy + High resection of rectum
Description: Laparoscopic total colectomy + High resection of rectum
Study NCT01200043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fructose restriction diet
Description: fruits and vegetables only
Study NCT01471847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 + Trastuzumab Phase l/Phase ll)
Description: Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy).
Study NCT01471847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib + Capecitabine (Phase II)
Description: If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start
Study NCT01844219 — intervention group
Intervention type: PROCEDURE
Intervention: elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)
Study NCT01802697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IdeS
Study NCT01802697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02796664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: Korean Red Ginseng extract tablet (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
Study NCT02796664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.5 grams/tablet, 2 tablets twice a day) daily for 12 months.
Study NCT03444116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Motion Analysis
Description: Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
Study NCT03444116 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sterEOS Imaging of Lower Extremities
Description: Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
Study NCT03444116 — intervention group
Intervention type: BEHAVIORAL
Intervention: Surveys
Description: 9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
Study NCT00543686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Intake of Montelukast
Study NCT00543686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Intake of Fluticasone
Study NCT04182152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Description: Indocyanine green (ICG) was diluted with saline to 0.5mg/mL, and injected 0.6mL/site.
Study NCT04182152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy
Description: Electromagnetic navigation bronchoscopy (ENB) allows physicians to access peripheral lung nodules with high accuracy and provides a working channel for ICG injection.
Study NCT04182152 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hook wire
Description: Hook wire is a puncture locating needle with a hook head that is about 1 cm in length and 30 cm metal wire behind. Through the puncture path planned based on CT scan, hook wire puncture percutaneously into the chest cavity to reach the lesion for localization.
Study NCT01987271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation
Description: A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School physical education class
Description: Children participated only in school physical education classes only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taekwondo
Description: Children participated only in taekwondo training only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Martial arts
Description: Children participated only in martial arts training only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Climbing
Description: Children participated only in climbing training only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volleyball
Description: Children participated only in volleyball training only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artistic gymnastics
Description: Children participated only in artistic gymnastics training only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming
Description: Children participated only in swimming training only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: Children participated only in dance training only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basketball
Description: Children participated only in basketball training only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrestling
Description: Children participated only in wrestling training only.
Study NCT03201302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Football (soccer)
Description: Children participated only in football (soccer) training only.